Drug intelligence / Profile preview

SYS6063

Development stage: Phase 1
Lead developer: CSPC Pharmaceutical Group
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

SYS6063 is an autologous, dual-targeting chimeric antigen receptor T-cell (CAR-T) therapy directed against CD19 and B-cell maturation antigen (BCMA). Developed by CSPC Pharmaceutical Group (specifically its subsidiary CSPC Zhongqi Pharmaceutical Technology), SYS6063 is designed to treat autoimmune disorders by inducing deep and durable depletion of the B-cell lineage, including both mature B cells and long-lived plasma cells. The therapy is currently under investigation in a Phase 1 clinical trial for patients with relapsed or refractory systemic lupus erythematosus (SLE) who have failed standard-of-care treatments, including biologic therapies.

Other names: anti-CD19/BCMA CAR-T

Targets

BCMA (B-cell maturation antigen)CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on SYS6063.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SYS6063.